ByTrending Posts
AI’s R&D Acceleration in Biopharma: Proven Power or…
AI is accelerating biopharma R&D where data abundance meets repeatable decisions—delivering 30-50% timeline compression in target ID and…
Agentic AI in Biopharma R&D: From Hype to…
Agentic AI shifts biopharma R&D from static predictions to dynamic, self-executing agent swarms that plan, act, validate, and…
How Are Biopharma Giants Deploying Agentic AI to…
This executive update expands on majors like Lilly, BMS, Pfizer, GSK, Novo, plus Roche, Merck, Sanofi, and AstraZeneca,…
What If HER2 Resistance Was Over? Henlius Doses…
Shanghai, China – March 3, 2026 – Henlius Biotech, Inc. (HKEX: 2696), a global biopharmaceutical leader in oncology innovation,…
BMS’s Chinese-Licensed ADC CC-1234 Delivers 52% ORR, 14-Month…
Published by BioNextAI Media – Bristol Myers Squibb (NYSE: BMY) unveiled compelling Phase 2 data for CC-1234, its next-generation…
Atrium Therapeutics Spins Out with $270M Cash from…
Published by BioNextAI Media – Atrium Therapeutics (Nasdaq: ATRM) launched as an independent public company following Novartis’ $12 billion…
Azitra Spotlights ATR-12 Phase 1b Data at BIO…
Published by BioNextAI Media – Azitra, Inc. (NYSE American: AZTR) takes center stage at the BIO Investment & Growth…
BioMarin’s Roctavian Withdrawal—$240M Q4 Charge, <200 U.S. Patients…
Published by BioNextAI Media – BioMarin Pharmaceutical Inc. voluntarily withdrew its pioneering hemophilia A gene therapy ROCTAVIAN (valoctocogene roxaparvovec-rvox)…
Boehringer’s Hernexeos Secures Record 44-Day FDA Nod via…
Published by BioNextAI Media – Boehringer Ingelheim’s HERNEXEOS (zongertinib tablets) snagged ultra-fast FDA accelerated approval in just 44 days…
Trending Posts
Latest Stories
How Does Novo Nordisk Transform Metabolic Leadership Into Multi-Billion Dollar Dominance Through 2030?
Novo Nordisk executes a “multi-mechanism obesity fortress” strategy under new CEO Mike Doustdar, reallocating R&D firepower from…
How Does AstraZeneca Transform ADC Dominance Into an $80 Billion Revenue Juggernaut by 2030?
AstraZeneca masterminds an “oncology everywhere” empire through surgical deployment of 20+ late-stage novel molecular entities across oncology…
How Does Roche’s TA-Wise Fortress Strategy Conquer 2030 LOE Cliffs Amid Obesity Wars?
Roche orchestrates a pharma-diagnostics juggernaut, surgically allocating 60% of R&D across five therapeutic arenas while weaponizing FoundationOne/Flatiron (covering…
What Drives Novartis’ Pipeline Dominance Through 2030?
Novartis’ clinical pipeline exemplifies a “focus factory” strategy, ruthlessly prioritizing 30+ high-ROI NMEs across five…
Gallery
